Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Patient-centricity

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Orphan indication? No easy access

Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

Interview: Beate Wieseler, IQWIG

Head of the department of drug assessment at the German HTA body on taking a pragmatic approach to comparing medicines

- PMLiVE

IMS Health acquires HGS Europe

Founders Graeme and Angela McFarlane bring HGS' market access services to IMS' UK team

Interview: Allan Hillgrove, Boehringer

Boehringer’s head of sales and marketing on access, partnerships and China on an important year for the German pharma company

Putin – pharma’s friend or foe in Russia?

Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market

- PMLiVE

VIDEO interview: Neil Weir, UCB

Senior vice president of global research at UCB discusses the importance of patient-centricity and the value of collaboration

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links